Management of Thrombocytopenia in Patients with JAK-2 Mutations

Risk Stratification and Management Approach

The National Comprehensive Cancer Network recommends risk stratification for JAK-2 mutation positive patients, with cytoreductive therapy recommended for high-risk patients and dose modifications of anticoagulation when platelet counts fall below 50 × 10^9/L 1, 2
For high-risk patients, the National Comprehensive Cancer Network suggests first-line therapy with cytoreductive therapy using hydroxyurea or interferon-alpha, with a target platelet count in the normal range while monitoring for cytopenia 1, 3, 4
The National Comprehensive Cancer Network recommends antiplatelet therapy with low-dose aspirin for vascular symptoms in high-risk patients 1

When platelet count is >50 × 10^9/L, the Journal of Thrombosis and Haemostasis suggests continuing full therapeutic anticoagulation if indicated for thrombosis, and maintaining cytoreductive therapy with close monitoring 1, 2, 5, 6
When platelet count is 25-50 × 10^9/L, the Journal of Thrombosis and Haemostasis recommends modifying anticoagulation dose to 50% or prophylactic dose if anticoagulation is required, and considering temporary dose reduction of cytoreductive therapy 1, 5, 6
When platelet count is <25 × 10^9/L, the Journal of Thrombosis and Haemostasis suggests considering withholding anticoagulation unless high-risk thrombotic features are present, and temporarily discontinuing cytoreductive therapy until platelet recovery 5, 6

For patients requiring anticoagulation, the Journal of Thrombosis and Haemostasis recommends prioritizing therapeutic anticoagulation with platelet support if needed for acute thrombosis, and considering a dose-modified anticoagulation approach beyond 30 days 5, 6
The Journal of Thrombosis and Haemostasis suggests low molecular weight heparin as the preferred anticoagulant over direct oral anticoagulants in patients with cancer-associated thrombosis and thrombocytopenia 5, 6

The National Comprehensive Cancer Network recommends regular complete blood counts to assess response to therapy and monitor for cytopenias, and bone marrow examination to rule out disease progression to myelofibrosis before initiating cytoreductive therapy 1, 2, 4